Cleerly, a NYC-based heart disease care company, closed a Series C financing round of $192m.
This round, which brought the total raised by the health care company to $248m, was led by funds and accounts advised by T. Rowe Price Associates, Inc. and T. Rowe Price Investment Management, Inc., and Fidelity Management and Research Company, which were joined by additional investors including Sands Capital, Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds, Mirae Asset Capital, Peter Thiel, Breyer Capital, and Novartis, as well as existing investors Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures and DigiTx Partners.
The company intends to use the funds to expand its team, extend its commercial reach to broaden patient and physician access to its comprehensive technology-enabled care pathway across the entire continuum of disease presentation—from early diagnosis of heart disease to ensuring that ongoing treatments are effective for those who have that elevated risk or symptoms, and invest in additional large-scale outcomes research. Cleerly has more than a dozen ongoing multicenter clinical trials, including an international registry enrolling more than 100,000 patients over the next decade – making it the largest cardiovascular phenotype outcomes study ever performed.
Led by James Min, MD, FACC, FESC, MSCCT, CEO and founder, Cleerly leverages FDA-cleared, value-based diagnostic solutions driven by machine intelligence to enable comprehensive phenotyping of coronary artery disease, as determined from advanced non-invasive CT imaging. Its AI-enabled approach to evaluating coronary computed tomography (CT) angiograms allows physicians to easily identify, characterize and qualify atherosclerosis (plaque) build-up in the walls of the heart arteries. This information promotes an accurate understanding of a patient’s risk of heart attack and represents a marked shift from the way that heart disease has been historically assessed using indirect surrogate markers of disease.
FinSMEs